论文部分内容阅读
目的:评价外周血造血干细胞移植(PBSCT)治疗血液病的临床疗效及并发症。方法:回顾性分析接受HSCT的125例血液病患者的临床资料。结果:123例患者成功获得造血重建,中性粒细胞计数≥0.5×109/L平均时间为11.5d,血小板计数≥20×109/L平均时间为14.8d;allo-HSCT组急性移植物抗宿主病(aGVHD)发生率为12.8%(6/47),慢性移植物抗宿主病(cGVHD)发生率为23.4%(11/47),移植相关病死率4.2%(2/47)。中位随访时间12(0～58)个月,复发率在自体移植和异基因移植患者中分别为26.9%(21/78)和10.6%(5/47),总复发率为20.8%。auto-HSCT组和allo-HSCT组总生存率(OS)、无病生存率(DFS)Meier曲线差异无统计学意义。结论:HSCT造血重建快,移植相关并发症较少,是一种安全而有效的治疗方法。
Objective: To evaluate the clinical efficacy and complications of peripheral blood stem cell transplantation (PBSCT) in the treatment of hematological diseases. Methods: The clinical data of 125 patients with hematological diseases receiving HSCT were retrospectively analyzed. Results: 123 patients achieved hematopoietic reconstitution successfully, the mean time of neutrophil count≥0.5 × 109 / L was 11.5d, the average platelet count≥20 × 109 / L was 14.8d. The acute graft versus host The incidence of aGVHD was 12.8% (6/47). The incidence of chronic graft-versus-host disease (cGVHD) was 23.4% (11/47) and the transplant-related mortality was 4.2% (2/47). The median follow-up time was 12 (0-58) months. The recurrence rate was 26.9% (21/78) and 10.6% (5/47) respectively in autologous and allograft recipients, with a total recurrence rate of 20.8%. There was no significant difference in the overall survival (OS) and the disease free survival (DFS) Meier between the auto-HSCT group and the allo-HSCT group. CONCLUSION: HSCT has the advantages of quick hematopoietic reconstitution, fewer complications related to transplantation and is a safe and effective treatment.